Trial Profile

An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Paclitaxel
Indications Early breast cancer
Focus Adverse reactions
Sponsors Roche

07 Jul 2021 Status changed from active, no longer recruiting to completed.
06 Apr 2021 Planned End Date changed from 28 Dec 2020 to 11 Jun 2021.
06 Apr 2021 Planned primary completion date changed from 28 Dec 2020 to 11 Jun 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com